Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eupraxia PharmaceuticalsTSX:EPRX +6.80%34 3-Year ROIIC % is 74,582.05 as of Dec. 2025, which is 59926% above its 10-year median of 124.25. GuruFocus rates TSX:EPRX with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,322 Biotechnology companies, Eupraxia Pharmaceuticals ranks better than 99.85% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Eupraxia Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 74,582.05%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Eupraxia Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
TSX:EPRX's 3-Year ROIIC % is ranked better than 99.85% of 1322
companies
in the Biotechnology industry
Industry Median: -4.835
vs TSX:EPRX: 74582.05
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Eupraxia Pharmaceuticals 3-Year ROIIC % Related Terms
Eupraxia Pharmaceuticals 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSX:EPRX vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Eupraxia Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eupraxia Pharmaceuticals 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Eupraxia Pharmaceuticals's 3-Year ROIIC % falls into.
Eupraxia Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -53.02 (Dec. 2025) - -23.933 (Dec. 2022) )
/
( 1.558 (Dec. 2025) - 1.597 (Dec. 2022) )
=
-29.087
/
-0.039000000000023
=
74,582.05%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Eupraxia Pharmaceuticals (TSX:EPRX) has a 3-Year ROIIC % of 74,582.05 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Eupraxia Pharmaceuticals and its competitors. This is 59926% above median its historical median of 124.25. According to the industry distribution chart, Eupraxia Pharmaceuticals ranks #2 out of 1322 companies in the Biotechnology industry, placing it in the top 0.2%.
Is Eupraxia Pharmaceuticals' 3-Year ROIIC % too high?
Eupraxia Pharmaceuticals' current 3-Year ROIIC % of 74,582.05 is 59926% above median its 10-year median of 124.25. Based on the distribution chart, Eupraxia Pharmaceuticals ranks #2 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eupraxia Pharmaceuticals ranks #2 out of 1322 companies for 3-Year ROIIC %. This places Eupraxia Pharmaceuticals in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Eupraxia Pharmaceuticals and its competitors. Eupraxia Pharmaceuticals's current 3-Year ROIIC % is 74,582.05, which is 59926% above median its own 10-year median of 124.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (TSX:EPRX) has a current 3-Year ROIIC % of 74,582.05. The current 3-Year ROIIC % is 74,582.05, which is 59926% above median its 10-year median of 124.25. Eupraxia Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (TSX:EPRX), the current 3-Year ROIIC % is 74,582.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
34GF Score
Get the complete analysis for TSX:EPRX
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:EPRX has been successfully added to your 
